Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2013

01.09.2013 | Topic Review

Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature

verfasst von: Ana-Maria Vranceanu, Vanessa L. Merker, Elyse Park, Scott R. Plotkin

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to review the literature on quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis, and to identify the specific aspects of quality of life that were studied and reported in this population. We also set out to report predictors of quality of life. Published research reports were included if they described quality of life in this population and met methodological quality according to a list of predefined criteria. Eight studies (7 in NF1, 1 in NF2, 0 in schwannomatosis), conducted between 2001 and 2013, met inclusion criteria. The methodological quality of the eight studies was mostly high according to ratings by predefined criteria. Most studies reported that patients with NF experience decreased quality of life when compared to the general population. Visibility and disease severity were strong predictors of skin-specific quality of life in NF1 patients. However, the majority of findings regarding predictors of quality of life were weak or inconclusive. Given the decreased quality of life in NF patients, it is important to examine more comprehensively the psychosocial factors in this population, especially in patients with NF2 and schwannomatosis. Mind body interventions that address these domains may provide comprehensive and efficacious long term treatment.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332PubMedCrossRef Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332PubMedCrossRef
2.
Zurück zum Zitat Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47–E53PubMed Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47–E53PubMed
3.
Zurück zum Zitat Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81–E86PubMed Lu-Emerson C, Plotkin SR (2009) The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81–E86PubMed
4.
Zurück zum Zitat Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76PubMedCrossRef Antinheimo J, Sankila R, Carpen O, Pukkala E, Sainio M, Jaaskelainen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76PubMedCrossRef
5.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCrossRef
6.
Zurück zum Zitat Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM (2004) Systematic review of prognostic cohort studies on shoulder disorders. Pain 109:420–431PubMedCrossRef Kuijpers T, van der Windt DA, van der Heijden GJ, Bouter LM (2004) Systematic review of prognostic cohort studies on shoulder disorders. Pain 109:420–431PubMedCrossRef
7.
Zurück zum Zitat Scholten-Peeters GG, Verhagen AP, Bekkering GE, van der Windt DA, Barnsley L, Oostendorp RA, Hendriks EJ (2003) Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain 104:303–322PubMedCrossRef Scholten-Peeters GG, Verhagen AP, Bekkering GE, van der Windt DA, Barnsley L, Oostendorp RA, Hendriks EJ (2003) Prognostic factors of whiplash-associated disorders: a systematic review of prospective cohort studies. Pain 104:303–322PubMedCrossRef
8.
Zurück zum Zitat Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G (2000) Physical risk factors for neck pain. Scand J Work Environ Health 26:7–19PubMedCrossRef Ariens GA, van Mechelen W, Bongers PM, Bouter LM, van der Wal G (2000) Physical risk factors for neck pain. Scand J Work Environ Health 26:7–19PubMedCrossRef
9.
Zurück zum Zitat Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A (2001) Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 137:1421–1425PubMedCrossRef Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A (2001) Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 137:1421–1425PubMedCrossRef
10.
Zurück zum Zitat Granstrom S, Langenbruch A, Augustin M, Mautner VF (2012) Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology 224:160–167PubMedCrossRef Granstrom S, Langenbruch A, Augustin M, Mautner VF (2012) Psychological burden in adult neurofibromatosis type 1 patients: impact of disease visibility on body image. Dermatology 224:160–167PubMedCrossRef
11.
Zurück zum Zitat Cosyns M, Mortier G, Janssens S, Van BJ (2012) Voice-related quality of life in adults with neurofibromatosis type 1. J Voice 26:e57–e62PubMedCrossRef Cosyns M, Mortier G, Janssens S, Van BJ (2012) Voice-related quality of life in adults with neurofibromatosis type 1. J Voice 26:e57–e62PubMedCrossRef
12.
Zurück zum Zitat Langenbruch AK, Augustin M, Granstrom S, Kluwe L, Mautner VF (2011) Clinical and healthcare status of patients with neurofibromatosis type 1. Br J Dermatol 165:225–227PubMedCrossRef Langenbruch AK, Augustin M, Granstrom S, Kluwe L, Mautner VF (2011) Clinical and healthcare status of patients with neurofibromatosis type 1. Br J Dermatol 165:225–227PubMedCrossRef
13.
Zurück zum Zitat Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG (2010) The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291–299PubMedCrossRef Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG (2010) The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291–299PubMedCrossRef
14.
Zurück zum Zitat Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D (2009) Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215–220PubMedCrossRef Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D (2009) Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215–220PubMedCrossRef
15.
Zurück zum Zitat Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P (2006) Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A 140A:1893–1898CrossRef Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P (2006) Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A 140A:1893–1898CrossRef
16.
Zurück zum Zitat Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL (2013) Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes 11:21PubMedCrossRef Nutakki K, Hingtgen CM, Monahan P, Varni JW, Swigonski NL (2013) Development of the adult PedsQL neurofibromatosis type 1 module: initial feasibility, reliability and validity. Health Qual Life Outcomes 11:21PubMedCrossRef
17.
Zurück zum Zitat Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRef
18.
Zurück zum Zitat Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ (1997) Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433–1440PubMedCrossRef Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ (1997) Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 133:1433–1440PubMedCrossRef
19.
Zurück zum Zitat Samuelsson B, Riccardi VM (1989) Neurofibromatosis in Gothenburg, Sweden. III. Psychiatric and social aspects. Neurofibromatosis 2:84–106PubMed Samuelsson B, Riccardi VM (1989) Neurofibromatosis in Gothenburg, Sweden. III. Psychiatric and social aspects. Neurofibromatosis 2:84–106PubMed
20.
Zurück zum Zitat Bull AA, Meyerowitz BE, Hart S, Mosconi P, Apolone G, Liberati A (1999) Quality of life in women with recurrent breast cancer. Breast Cancer Res Treat 54:47–57PubMedCrossRef Bull AA, Meyerowitz BE, Hart S, Mosconi P, Apolone G, Liberati A (1999) Quality of life in women with recurrent breast cancer. Breast Cancer Res Treat 54:47–57PubMedCrossRef
21.
Zurück zum Zitat Downe-Wamboldt B, Butler L, Coulter L (2006) The relationship between meaning of illness, social support, coping strategies, and quality of life for lung cancer patients and their family members. Cancer Nurs 29:111–119PubMedCrossRef Downe-Wamboldt B, Butler L, Coulter L (2006) The relationship between meaning of illness, social support, coping strategies, and quality of life for lung cancer patients and their family members. Cancer Nurs 29:111–119PubMedCrossRef
22.
Zurück zum Zitat Carslon LE, Bultz BD (2004) Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case of economic analyses. Psycho-oncology 13:347–837 Carslon LE, Bultz BD (2004) Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case of economic analyses. Psycho-oncology 13:347–837
Metadaten
Titel
Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature
verfasst von
Ana-Maria Vranceanu
Vanessa L. Merker
Elyse Park
Scott R. Plotkin
Publikationsdatum
01.09.2013
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2013
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-013-1195-2

Weitere Artikel der Ausgabe 3/2013

Journal of Neuro-Oncology 3/2013 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.